Sylvant (Siltuximab)
siltuximab 400 mg injection, 1 vial · INJECTION · PBS code 12934R
AUTHORITY_REQUIREDWhat it costs
AU$3117.1 PBS-determined price per 2 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2022-04-01.
- • Repeats: 4.
- • PBS program: HS.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Idiopathic multicentric Castleman disease (iMCD)
Initial treatment
Patient must have a diagnosis of iMCD consistent with the latest international, evidence-based consensus diagnostic criteria for this condition with the relevant diagnostic findings documented in the patient's medical records; AND
The condition must not be, to the prescriber's best knowledge, any of the following diseases that can mimic iMCD: (i) human herpes virus-8 infection, (ii) an Epstein-Barr virus-lymphoproliferative disorder, (iii) an acute/uncontrolled infection (e.g. cytomegalovirus, toxoplasmosis, human immunodeficiency virus, tuberculosis) leading to inflammation with adenopathy, (iv) an autoimmune/autoinflammatory disease, (v) a malignant/lymphoproliferative disorder; AND
Must be treated by a haematologist; or
Must be treated by a medical physician working under the supervision of a haematologist; AND
Patient must be undergoing treatment through this treatment phase once only in a lifetime, where the full number of repeats are prescribed; or
Patient must be undergoing treatment through this treatment phase for up to the first 5 doses in a lifetime, where the full number of repeats was not prescribed with the first prescription.
Prescribe the most efficient combination of vials/strengths based on the patient's body weight to keep any amount of unused drug to a minimum.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Idiopathic multicentric Castleman disease (iMCD)
Continuing treatment
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
Patient must not have developed disease progression while receiving treatment with this drug for this condition; AND
Must be treated by a haematologist; or
Must be treated by a medical physician working under the supervision of a haematologist.
Prescribe the most efficient combination of vials/strengths based on the patient's body weight to keep any amount of unused drug to a minimum.
Sponsor: Recordati Rare Diseases Australia Pty. Ltd. ABN 26 627 263 094
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.